Correction: Cost-of-illness in psoriasis: Comparing inpatient and outpatient therapy (PLoS ONE 8, 10 (e78152) DOI: 10.1371/journal.pone.0078152);Cost-of-Illness in Psoriasis: Comparing Inpatient and Outpatient Therapy

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Steinke, Sabine I B ^a,b   Peitsch, Wiebke K ^b   Ludwig, Alexander ^c,d   Goebeler, Matthias ^b,e  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d MAX PLANCK INSTITUTE FOR SOCIAL LAW AND SOCIAL POLICY   (Germany)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; EFALIZUMAB; ETANERCEPT; FUMARIC ACID; INFLIXIMAB; METHOTREXATE; PRESCRIPTION DRUG; RETINOID; SALICYLIC ACID; UREA; VITAMIN D; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE DURATION; FEMALE; FOLLOW UP; GERMANY; HEALTH CARE COST; HOSPITAL CARE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PHOTOTHERAPY; PSORIASIS; PSORIASIS VULGARIS; REMISSION; RETROSPECTIVE STUDY; TREATMENT DURATION; AMBULATORY CARE; ANALYSIS OF VARIANCE; ECONOMICS; HOSPITAL COST; MIDDLE AGED; REGRESSION ANALYSIS; STATISTICS AND NUMERICAL DATA; TOPICAL DRUG ADMINISTRATION; VERY ELDERLY;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; FEMALE; GERMANY; HOSPITAL COSTS; HUMANS; MALE; MIDDLE AGED; PHOTOTHERAPY; PSORIASIS; REGRESSION ANALYSIS; RETINOIDS; RETROSPECTIVE STUDIES; VITAMIN D;

EID: 84886024661     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/annotation/cf71846b-1fa5-46bb-ac82-d5884b17451d     Document Type: Erratum

References (37)

1. Deutsche Agentur für Health Technology Assessment des Deutschen Instituts für Medizinische Dokumentation und Information (2006) Schriftenreihe Health Technology Assessment (HTA). Köln. 15-46, 91-94 p.
2. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K, (2008) Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology (Basel) 216(4):: 366-372. doi:10.1159/000119415. PubMed: 18319601.
3. Galadari I, Rigel E, Lebwohl M, (2001) The cost of psoriasis treatment. J Eur Acad Dermatol Venereol 15(4):: 290-291. doi:10.1046/j.1468-3083.2001.00257.x. PubMed: 11730031.
4. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG, (2002) The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 46(6):: 850-860. doi:10.1067/mjd.2002.119669. PubMed: 12063481.
5. Morrow T, (2006) Cost-effective psoriasis treatment may demand creative coverage rules. Manag Care Volumes 15: 61-63. PubMed: 16749523.
6. Schmitt JM, Ford DE, (2006) Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology (Basel) 213(2):: 102-110. doi:10.1159/000093848.
7. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR, (2005) Inpatient management of severe psoriasis. J Drugs Dermatol 4(5):: 564-570. PubMed: 16167414.
8. Stern RS, (2003) Inpatient hospital care for psoriasis: a vanishing practice in the United States. J Am Acad Dermatol 49(3):: 445-450. doi:10.1067/S0190-9622(03)00858-2. PubMed: 12963908.
9. Braun-Falco O, Plewig G, Wolff HH, Burgdorff WHC, Landthaler M, editors (2005) Dermatologie und Venerologie. Heidelberg: Springer Verlag. pp. pp. 476-497.
10. Koo J, Lebwohl M, (1999) Duration of remission of psoriasis therapies. J Am Acad Dermatol 41(1):: 51-59. doi:10.1016/S0190-9622(99)70406-8. PubMed: 10411411.
11. Nast A, Boehncke W, Mrowietz U, Ockenfels H, Philipp S, et al. (2011) S3 Leitlinie zur Therapie der Psoriasis vulgaris - Update 2011. J Dtsch Dermatol Ges 9 (Suppl 2),:: S1-104. doi:10.1111/j.1610-0379.2011.07680.supp.x.
12. Youn JI, Kim BK, Suh DH, (1998) The effectiveness of modified ingram therapy compared with severity of psoriasis. J Dermatol 25(2):: 112-117. PubMed: 9563279.
13. Fluhr JW, Junger M, (2007) The price for treatment of chronic skin diseases: different approaches. Dermatology (Basel) 214(1):: 6-7. doi:10.1159/000096905. PubMed: 17191040.
14. Hartman M, Prins M, Swinkels OQJ, Severens JL, Boo T, et al. (2002) Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment. Br J Dermatol 147(3):: 538-544. doi:10.1046/j.1365-2133.2002.04920.x. PubMed: 12207597.
15. Schmitt J, Heese E, Wozel G, Meurer M, (2007) Effectiveness of inpatient treatment on quality of life and clinical disease severity in atopic dermatitis and psoriasis vulgaris- a prospective study. Dermatology (Basel) 214(1):: 68-76. doi:10.1159/000096916. PubMed: 17191051.
16. Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR, (2006) The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatol Treat 17(1):: 29-37. doi:10.1080/09546630500504754. PubMed: 16467021.
17. Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J, (2003) Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother Volumes 4: 1525-1533. doi:10.1517/14656566.4.9.1525. PubMed: 12943482.
18. Opmeer BC, Heydendael VMR, Borgie CAJM de, Spuls PI, Bossuyt PMM, et al. (2004) Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol 140(6):: 685-690. doi:10.1001/archderm.140.6.685. PubMed: 15210458.
19. Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR, (2006) The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatol Treat 17(1):: 29-37. doi:10.1080/09546630500504754. PubMed: 16467021.
20. Berger K, Ehlken B, Kugland B, Augustin M, (2005) Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 3(7):: 511-518. doi:10.1111/j.1610-0387.2005.05729.x. PubMed: 15967010.
21. Hahn M, [!(surname)!], (2005) Gesundheitsökonomische Aspekte der Psoriasistherapie. Hautarzt Volumes 56: 576-580. doi:10.1007/s00105-005-0946-1. PubMed: 15815889.
22. Schöffski O, Augustin M, Prinz J, Rauner K, Schubert E, et al. (2007) Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges Volumes 5: 209-218. doi:10.1111/j.1610-0387.2007.06240.x. PubMed: 17338796.
23. Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, et al. (2006) Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology (Basel) 212(2):: 137-144. doi:10.1159/000090654. PubMed: 16484820.
24. Miguel R de, el-Azhary R, (2009) Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis. Int J Dermatol 48(6):: 653-658. doi:10.1111/j.1365-4632.2009.04012.x. PubMed: 19538381.
25. Finzi AF, Mantovani LG, Belisari A, (2001) The cost of hospital-related care of patients with psoriasis in Italy based on the AISP study. Associazione Italiana Studi Psoriasi. J Eur Acad Dermatol Venereol 15(4):: 320-324. doi:10.1046/j.1468-3083.2001.00256.x. PubMed: 11730042.
26. Fonia A, Jackson K, Lereun C, Grant DM, Barker J, (2010) A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol 163(4):: 807-816. doi:10.1111/j.1365-2133.2010.09944.x. PubMed: 20662837.
27. Schwartz F, Badura B, Busse R, Leidl R, Raspe H, et al. editors (2003) Das Public-Health-Buch. Der Effizienz auf der Sput. Eine Einführung in die ökonomische Evaluation. München: Urban & Fischer Verlag. pp. pp. 461-484.
28. Poulin Y, Langley RG, Teixeira HD, Martel MJ, Cheung S, (2009) Biologics in the treatment of psoriasis: clinical and economic overview. J Cutan Med Surg 13 (Suppl 2):: S49-S57. PubMed: 19799827.
29. Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH, (2009) Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol 160(6):: 1264-1272. doi:10.1111/j.1365-2133.2008.08962.x. PubMed: 19120346.
30. Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, et al. (2011) Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatol Treat 22(2):: 65-74. doi:10.3109/09546630903551258. PubMed: 20443663.
31. Beyer V, Wolverton SE, (2010) Recent trends in systemic psoriasis treatment costs. Arch Dermatol 146(1):: 46-54. doi:10.1001/archdermatol.2009.319. PubMed: 20083692.
32. Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, et al. (2008) The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 59(5):: 772-780. doi:10.1016/j.jaad.2008.06.043. PubMed: 19119095.
33. Kimball AB, Guérin A, Tsaneva M, Yu AP, Wu EQ, et al. (2011) Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol 25(2):: 157-163. doi:10.1111/j.1468-3083.2010.03730.x. PubMed: 20561129.
34. Ghatnekar O, Ljungberg A, Wirestrand LE, Svensson A, (2012) Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden- a cross-sectional study. Eur J Dermatol 22(2):: 238-245. PubMed: 22361745.
35. Balkrishnan R, Bhosle MJ, Camacho FT, Anderson RT, (2006) Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. J Urol 175(3 Pt 1):: 1067-1072; discussion:.
36. Schaarschmidt ML, Schmieder A, Umar N, Terris D, Goebeler M, et al. (2011) Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol 147(11):: 1285-1294. doi:10.1001/archdermatol.2011.309. PubMed: 22106115.
37. Schaarschmidt ML, Umar N, Schmieder A, Terris DD, Goebeler M, et al. (2013) Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol 27(2):: 187-198. doi:10.1111/j.1468-3083.2011.04440.x. PubMed: 22225546.